Establishment Labs Holdings Inc. $ESTA Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC cut its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 14.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 651,559 shares of the company’s stock after selling 108,638 shares during the period. Establishment Labs makes up 2.6% of Rice Hall James & Associates LLC’s holdings, making the stock its 5th largest position. Rice Hall James & Associates LLC’s holdings in Establishment Labs were worth $47,486,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. William Blair Investment Management LLC lifted its position in Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after buying an additional 152,299 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Establishment Labs by 59.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock worth $8,445,000 after buying an additional 43,164 shares in the last quarter. Bamco Inc. NY lifted its position in Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after buying an additional 274,287 shares in the last quarter. Simplify Asset Management Inc. lifted its position in Establishment Labs by 92.1% during the 4th quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares in the last quarter. Finally, Portolan Capital Management LLC lifted its position in Establishment Labs by 24.7% during the 3rd quarter. Portolan Capital Management LLC now owns 155,096 shares of the company’s stock worth $6,357,000 after buying an additional 30,704 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Stock Up 2.5%

Shares of ESTA opened at $84.21 on Tuesday. Establishment Labs Holdings Inc. has a 52 week low of $33.35 and a 52 week high of $86.00. The firm has a market cap of $2.48 billion, a P/E ratio of -56.52 and a beta of 1.11. The firm’s 50-day simple moving average is $69.33 and its 200 day simple moving average is $69.28. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. During the same quarter last year, the company posted ($0.70) EPS. The firm’s quarterly revenue was up 44.7% on a year-over-year basis. On average, analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ESTA. Canaccord Genuity Group upped their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Mizuho upped their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Needham & Company LLC upped their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $87.14.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 330,000 shares of company stock worth $22,854,538. Company insiders own 9.99% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.